Many racetracks have succumbed to high real-estate prices in recent years, their sweeping turns or steep banking replaced by subdivisions or warehouses. At least for now, Virginia International ...

Investing.com - Leerink Partners reiterated an Outperform rating and $16.00 price target on Vir Biotechnology (NASDAQ:VIR) following Mirum’s acquisition of private company Bluejay. VIR shares, ...

The comedian Vir Das, who has gained international fame despite intense criticism in his native India, has taken up boxing. He says it’s “good prep for adversity.” Vir Das, a comedian, feels boxing is ...

Private Afrikaans university Akademia has officially started enrolling full-time students at its new Paarl campus in the Western Cape, setting the stage for the 2026 academic year. The campus, located ...

Vir Biotechnology, Inc. (NASDAQ:VIR), currently trading at $5.02, has seen its stock decline over 34% year-to-date, reflecting investor concerns despite its potential in treating serious infectious ...

As festivities for Independence Day begin, the centre on Thursday awarded Vir Chakra to nine Indian Air Force officers for their brave contributions in the service of the nation during Operation ...

NEW DELHI: As festivities for Independence Day begin, the centre on Thursday awarded Vir Chakra to nine Indian Air Force officers for their brave contributions in the service of the nation during ...

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $1.02 per share a year ago. These ...

Marianne De Backer, PhD, MBA, CEO of Vir Biotechnology, has led the company's pivot to focusing on cancer as well as infectious diseases. [Vir Biotechnology] Between launching clinical studies for its ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the second quarter ended June ...

Fintel reports that on July 11, 2025, Raymond James initiated coverage of Vir Biotechnology (NasdaqGS:VIR) with a Outperform recommendation. Analyst Price Forecast Suggests 232.11% Upside As of June ...

Vir Biotechnology, Inc. VIR shares soared 11.9% in the last trading session to close at $5.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...